+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID07762976

Risk-Adapted Chemotherapy Guided by EBV-DNA and MRI in Nasopharyngeal Carcinoma Patients Using De-concurrent Treatment Approach

Led by Fudan University · Updated on 2026-08-13

148

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a risk-adapted adjuvant therapy approach based on dynamic Epstein-Barr virus EBV DNA changes and MRI results in patients with nasopharyngeal carcinoma NPC. The study aims to determine if this tailored treatment improves the 2-year failure-free survival compared to a historical group receiving standard care. The trial focuses on patients with specific stages of NPC and uses a prospective single-center phase II design. Participants receive initial induction chemotherapy with gemcitabine and cisplatin, followed by intensity-modulated radiation therapy IMRT. After radiotherapy, patients are categorized into low, medium, or high risk based on EBV-DNA and MRI findings. The low-risk group undergoes clinical follow-up only, the medium-risk group receives capecitabine orally for eight cycles, and the high-risk group receives both tislelizumab intravenously and capecitabine orally for up to eight cycles, with possible maintenance of tislelizumab. During the study, participants undergo dynamic monitoring of EBV-DNA and MRI assessments. Researchers evaluate outcomes including 2-year failure-free survival, overall survival, locoregional and distant failure-free survival, adverse effects, and tumor response rates at various time points after IMRT. The trial monitors safety and treatment effects up to two years, with follow-up visits and evaluations throughout the period.

CONDITIONS

Brief Title

Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma

Research Team

X

Xiayun He, MD

F

Fen Xue, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here